Literature DB >> 22234781

A prospective cohort study challenging the effectiveness of population-based medical intervention for smoking cessation.

Hillel R Alpert1, Gregory N Connolly, Lois Biener.   

Abstract

OBJECTIVE: To examine the population effectiveness of nicotine replacement therapies (NRTs), either with or without professional counselling, and provide evidence needed to better inform healthcare coverage decisions.
METHODS: A prospective cohort study was conducted in three waves on a probability sample of 787 Massachusetts adult smokers who had recently quit smoking. The baseline response rate was 46%; follow-up was completed with 56% of the designated cohort at wave 2 and 68% at wave 3. The relationship between relapse to smoking at follow-up interviews and assistance used, including NRT with or without professional help, was examined.
RESULTS: About one-fourth of recent quitters at each wave reported to have relapsed by the subsequent interview. Odds of relapse were unaffected by use of NRT for >6 weeks either with (p=0.117) or without (p=0.159) professional counselling and were highest among prior heavily dependent persons who reported NRT use for any length of time without professional counselling (OR 2.68).
CONCLUSIONS: This study finds that persons who have quit smoking relapsed at equivalent rates, whether or not they used NRT to help them in their quit attempts. Cessation medication policy should be made in the larger context of public health, and increasing individual treatment coverage should not be at the expense of population evidence-based programmes and policies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22234781     DOI: 10.1136/tobaccocontrol-2011-050129

Source DB:  PubMed          Journal:  Tob Control        ISSN: 0964-4563            Impact factor:   7.552


  44 in total

1.  E-cigarettes May Impair Ability to Quit, but Other Explanations Are Possible.

Authors:  Alberto Donzelli
Journal:  Am J Public Health       Date:  2015-08-13       Impact factor: 9.308

2.  Reducing lung cancer and other tobacco-related cancers in Europe: smoking cessation is the key.

Authors:  Luke Clancy
Journal:  Oncologist       Date:  2013-12-06

3.  Relapse among cigarette smokers: the CARDIA longitudinal study - 1985-2011.

Authors:  Ralph S Caraballo; Judy Kruger; Kat Asman; Linda Pederson; Rachel Widome; Catarina I Kiefe; Brian Hitsman; David R Jacobs
Journal:  Addict Behav       Date:  2013-09-16       Impact factor: 3.913

4.  Design strategy for a smoking cessation trial of survival.

Authors:  Jonathan J Shuster
Journal:  Clin Transl Sci       Date:  2013-11-06       Impact factor: 4.689

5.  Knowledge, attitudes and beliefs towards e-cigarettes among e-cigarette users and stop smoking advisors in South East England: a qualitative study.

Authors:  Nancy Tamimi
Journal:  Prim Health Care Res Dev       Date:  2017-08-04       Impact factor: 1.458

6.  Kostygina et al. Respond.

Authors:  Ganna Kostygina; Lucinda England; Pamela M Ling
Journal:  Am J Public Health       Date:  2016-12       Impact factor: 9.308

7.  Enhancing tobacco quitline effectiveness: identifying a superior pharmacotherapy adjuvant.

Authors:  Stevens S Smith; Paula A Keller; Kate H Kobinsky; Timothy B Baker; David L Fraser; Terry Bush; Brooke Magnusson; Susan M Zbikowski; Timothy A McAfee; Michael C Fiore
Journal:  Nicotine Tob Res       Date:  2012-09-19       Impact factor: 4.244

Review 8.  Adolescent brain maturation and smoking: what we know and where we're headed.

Authors:  David M Lydon; Stephen J Wilson; Amanda Child; Charles F Geier
Journal:  Neurosci Biobehav Rev       Date:  2014-07-12       Impact factor: 8.989

Review 9.  Smoking and increased Alzheimer's disease risk: a review of potential mechanisms.

Authors:  Timothy C Durazzo; Niklas Mattsson; Michael W Weiner
Journal:  Alzheimers Dement       Date:  2014-06       Impact factor: 21.566

Review 10.  Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice.

Authors:  Henri-Jean Aubin; Amandine Luquiens; Ivan Berlin
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.